Back
Ernexa Therapeutics, Inc. 10K Form
Sell
27
ERNA
Ernexa Therapeutics, Inc.
Last Price:
$1.27
Seasonality Move:
3.2%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ERNA News And Ratings
See the #1 stock for the next 7 days that we like better than ERNA
ERNA Financial Statistics
Sales & Book Value
| Annual Sales: | $582K |
|---|---|
| Cash Flow: | $-1.3M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.45 |
| Price / Book: | 2.64 |
Profitability
| EPS (TTM): | -2.59550 |
|---|---|
| Net Income (TTM): | $-18.3M |
| Gross Margin: | $-1.2M |
| Return on Equity: | 0% |
| Return on Assets: | -288.35% |
Ernexa Therapeutics, Inc. Earnings Forecast
Key Ernexa Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 31 years for ERNA is -197.94%.
-
The Selling, General & Administrative Expenses for ERNA have been equal to 2,256.36% of Gross Profit Margin.
-
The Research & Development expenses have been 791.07% of Revenue.
-
The Net Earning history of ERNA is -7,652.75% of Total Revenues.
-
Per Share Earnings over the last 31 years have been positive in 12 years.
Ernexa Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ERNA |
| Website: | ernexatx.com |
Debt
| Debt-to-Equity Ratio: | 0.15 |
|---|---|
| Current Ratio: | 1.58 |
| Quick Ratio: | 1.42 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ERNA Technical Analysis vs Fundamental Analysis
Sell
27
Ernexa Therapeutics, Inc. (ERNA)
is a Sell
Is Ernexa Therapeutics, Inc. a Buy or a Sell?
-
Ernexa Therapeutics, Inc. stock is rated a SellThe current Ernexa Therapeutics, Inc. [ERNA] share price is $1.28. The Score for ERNA is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.